Abstract
AbstractLead optimization efforts that employed structure‐based drug design and physicochemical property based refinement lead to the discovery of title compound (XIII) which exhibits potent activity against PI3Kα and mTOR, good kinase selectivity, and robust ADMET properties as well as good oral bioavailability.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
